CVS Health Corp (CVS)
70.17
+0.00 (0.00%)
NYSE · Last Trade: Aug 19th, 5:40 AM EDT
Detailed Quote
Previous Close | 70.17 |
---|---|
Open | - |
Bid | 70.07 |
Ask | 70.44 |
Day's Range | N/A - N/A |
52 Week Range | 43.56 - 72.51 |
Volume | 767 |
Market Cap | 92.59B |
PE Ratio (TTM) | 19.55 |
EPS (TTM) | 3.6 |
Dividend & Yield | 2.660 (3.79%) |
1 Month Average Volume | 9,011,985 |
Chart
About CVS Health Corp (CVS)
CVS Health Corp is a diversified healthcare company that operates a vast network of retail pharmacies, providing prescription medications, over-the-counter products, and health and wellness services. In addition to its retail operations, CVS Health also offers pharmacy benefit management services, helping manage prescription drug costs for businesses and health plans. The company is involved in providing health insurance and health services through its various divisions, including a growing presence in digital health solutions and immunization services. By integrating pharmacy services with healthcare delivery, CVS Health aims to enhance patient care and improve health outcomes across the communities it serves. Read More
News & Press Releases
Michael Burry and Warren Buffett invested in UnitedHealth, signaling confidence in its sector and potential for earnings recovery by 2027.
Via Benzinga · August 18, 2025
Synergy CHC Corp. (NASDAQ: SNYR) is supercharging its retail expansion with a nationwide rollout of FOCUSfactor® Focus + Energy through EG America, the 6th largest U.S. convenience chain . The deal instantly places the functional brain health beverage in 1,600+ high-traffic locations , including Cumberland Farms, Turkey Hill, Tom Thumb (Albertsons Companies Inc. – NYSE: ACI), Loaf ’N Jug, and Minit Mart .
Via AB Newswire · August 18, 2025
Via Benzinga · August 18, 2025
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Via Chartmill · August 18, 2025
Costco won't sell abortion pill mifepristone in U.S. stores due to low demand amid pressure from religious groups.
Via Benzinga · August 16, 2025
In a striking display of market intervention and strategic investment, two major corporate developments are sending ripples through the financial world. The U.S. government is reportedly considering an unprecedented ownership stake in struggling chipmaker Intel (NASDAQ: INTC), signaling a direct and significant move to bolster domestic semiconductor manufacturing. Simultaneously,
Via MarketMinute · August 15, 2025
The financial markets are grappling with a perplexing economic puzzle as recent inflation data presents a contradictory picture. July 2025 saw the Producer Price Index (PPI) surge significantly, indicating rising wholesale costs for businesses, while the Consumer Price Index (CPI) remained relatively steady. This divergence has sent mixed signals to
Via MarketMinute · August 15, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Via Chartmill · August 15, 2025
Looking back on health insurance providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Cigna (NYSE:CI) and its peers.
Via StockStory · August 14, 2025
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare providers & services industry, including AMN Healthcare Services (NYSE:AMN) and its peers.
Via StockStory · August 14, 2025
Synergy CHC Corp. (NASDAQ: SNYR), a consumer health and wellness company, has reported its financial results for Q2 2025, marking its tenth consecutive quarter of profitability . The company posted revenue of $8.1 million, gross margin of 76.7%, and net income of $1.5 million—up 125% year-over-year—with earnings per share rising 86% to $0.17. EBITDA surged 136% to $3.8 million. See Entire Press Release.
Via AB Newswire · August 14, 2025
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Cencora (NYSE:COR) and the rest of the health insurance providers stocks fared in Q2.
Via StockStory · August 13, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Pediatrix Medical Group (NYSE:MD) and its peers.
Via StockStory · August 13, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CVS (CVS) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · August 13, 2025
Diversified healthcare company CVS Health (NYSE:CVS) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 8.4% year on year to $98.92 billion. Its non-GAAP profit of $1.81 per share was 23.9% above analysts’ consensus estimates.
Via StockStory · August 13, 2025
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Via StockStory · August 12, 2025
Synergy CHC Corp. (NASDAQ: SNYR), the consumer health powerhouse behind the FOCUSfactor® brand, is making headlines again as its CEO took to the airwaves to spotlight the company’s 25-year journey from brain-boosting tablets to energy drinks and weight management innovation.
Via AB Newswire · August 6, 2025
Palantir, Pfizer, Hims & Hers, Intel, UnitedHealth: Stocks Making The Biggest Moves Todaystocktwits.com
Via Stocktwits · August 5, 2025
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.
Via Chartmill · August 5, 2025
Dividend stocks are an ideal way to diversify your portfolio and also earn extra income.
Via The Motley Fool · August 2, 2025
Via Benzinga · August 1, 2025
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
Via Benzinga · August 1, 2025